A New Line of Sight Into

Targeted Cancer Therapies

Developing a Novel Class of Targeted
Alpha-Particle Radiopharmaceuticals

We are an alpha-particle radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.

Our new, proprietary class of theranostics enable the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.


Understanding Which Patients Will Respond to Therapy

See the Tumor – Determine patient response, image tumor and identify tumor location

Treat the Tumor – Demonstrated to kill cancer cells with the ability to optimize patient dosing based on diagnostic images

Development Pipeline

Get Notified:

Let us keep you up to date on news and information

Contact Us:

Viewpoint Molecular
Targeting, Inc.
2500 Crosspark Rd
Coralville, IA 52241
(865) 356-1861

Investor Relations
Jenene Thomas
(833) 475-8247